关键信息
-
基因名
LUZP6
- 应用
-
别名
Leucine zipper protein 6; LUZP6; LUZP6_HUMAN; Myeloproliferative disease-associated 6 kDa antigen
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q538Z0
-
表达区间
1-435aa
-
氨基酸序列
MAQAVWSRLGRILWLACLLPWAPAGVAAGLYELNLTTDSPATTGAVVTISASLVAKDNGSLALPADAHLYRFHWIHTPLVLTGKMEKGLSSTIRVVGHVPGEFPVSVWVTAADCWMCQPVARGFVVLPITEFLVGDLVVTQNTSLPWPSSYLTKTVLKVSFLLHDPSNFLKTALFLYSWDFGDGTQMVTEDSVVYYNYSIIGTFTVKLKVVAEWEEVEPDATRAVKQKTGDFSASLKLQETLRGIQVLGPTLIQTFQKMTVTLNFLGSPPLTVCWRLKPECLPLEEGECHPVSVASTAYNLTHTFRDPGDYCFSIRAENIISKTHQYHKIQVWPSRIQPAVFAFPCATLITVMLAFIMYMTLRNATQQKDMVEVADFDFSPMSDKNPEPPSGVRCCCQMCCGPFLLETPSEYLEIVRENHGLLPPLYKSVKTYTV
-
分子量
74.25 KDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
LUZP6, a member of the LUZP (Luzp-like protein) family, has garnered attention in recent years due to its potential role in various biological processes and diseases. This protein is thought to participate in cellular signaling pathways, particularly those involving stress responses and cell proliferation. Preliminary studies suggest that LUZP6 may be implicated in cancer progression and immune responses, making it a candidate for therapeutic targeting. The mechanisms by which LUZP6 exerts its effects are still under investigation, with researchers focusing on understanding its structure-function relationships and interaction networks. Notably, the production of recombinant LUZP6 proteins allows for detailed biochemical analyses, facilitating insights into its functional roles and potential as a biomarker or therapeutic target. As the demand for targeted interventions in disease management increases, studying proteins like LUZP6 is vital for developing novel strategies in precision medicine and biotechnology. The findings from ongoing research may provide significant contributions to our understanding of complex diseases and pave the way for innovative treatment modalities.
